- Home
- WENC vs TLSA Comparison
WENC vs TLSA Comparison
Compare WENC & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WENC | TLSA |
|---|---|---|
| Founded | 2025 | 2013 |
| Country | Mexico | United Kingdom |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.2M | 145.1M |
| IPO Year | 2026 | 2017 |
Fundamental Metrics
Financial Performance| Metric | WENC | TLSA |
|---|---|---|
| Price | $10.02 | $1.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.02 |
| AVG Volume (30 Days) | 18.9K | ★ 623.7K |
| Earning Date | N/A | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $166.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.89 | $0.76 |
| 52 Week High | $10.05 | $2.10 |
Technical Indicators
Market Signals| Indicator | WENC | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 58.41 | 45.91 |
| Support Level | $9.99 | $0.90 |
| Resistance Level | N/A | $1.21 |
| Average True Range (ATR) | 0.01 | 0.09 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 41.67 | 12.68 |
Price Performance
Historical ComparisonAbout WENC West Enclave Merger Corp. Ordinary Shares
West Enclave Merger Corp is a blank check company.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.